FDA On What Aduhelm AdCom Got Wrong: Statistics, Investigational Drugs, Patient Perspective

 
• By Brenda Sandburg
Alzheimer's
FDA answers critics in review documents for Alzheimer's disease drug Aduhelm • Source: Alamy

More from Approval Standards

More from Pathways & Standards